Géraldine Gebhart

Service(s) : Médecine nucléaire

geraldine.gebhart [at] bordet.be

Publications

Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

Auteurs : Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A
Année : 2021
Journal : Lancet Oncol

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Année : 2021
Journal : NPJ Breast Cancer

How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.

Auteurs : Mileva M, Artigas C, Gebhart G, Flamen P, Karfis I
Année : 2020
Journal : Hell J Nucl Med

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Auteurs : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart M, Sotiriou C, Jamieson SMF
Année : 2020
Journal : Br J Cancer

Added value of para-aortic surgical staging compared to <sup>18</sup>F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.

Auteurs : De Cuypere M, Lovinfosse P, Goffin F, Gennigens C, Rovira R, Duch J, Fastrez M, Gebhart G, Squifflet JL, Luyckx M, Charaf G, Crener K, Buxant F, Bucella D, Jouret M, Hustinx R, Kridelka F
Année : 2020
Journal : Eur J Surg Oncol

Plus de publications »

Géraldine Gebhart

Suivez-nous!

Le nouvel Institut Jules Bordet.

Languages

Contact